Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Stands to Pocket $43M in Convertible Debt to Help Pay for Drug Discovery

NEW YORK (GenomeWeb News) — DeCode Genetics today said it will pocket around $43 million in a convertible note placement, which it will use to pay for drug development programs and general corporate use.
Decode said it has commitments from investors to buy $65 million worth of senior convertible notes due in 2011. The debt will be convertible into Decode common stock at an initial conversion rate of 71.4286 shares per $1,000 principal amount of notes, equivalent to an initial conversion price of $14 per share.
The company said it may redeem the notes beginning April 20, 2009.
The company said the offering should close by Nov. 17.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.